CAS · 873054-44-5
Product Overview
Ivacaftor is a high-purity pharmaceutical-intermediates supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance | Off white solid |
|---|---|
| Purity | 99% min |
| Identification | IR |
| Water | 1.0% max |
| Any individual impurity | 0.5% max |
| Total impurities | 1.0% max |
Applications
Ivacaftor is primarily used in pharmaceutical applications as a therapeutic agent for the treatment of cystic fibrosis. It functions as a CFTR (cystic fibrosis transmembrane conductance regulator) potentiator, enhancing the gating activity of defective CFTR protein in patients with specific mutations. The compound is incorporated into oral formulations for clinical administration and is often studied in combination with other modulators to improve patient outcomes. In research and development, Ivacaftor is used to investigate CFTR-targeted therapies, evaluate drug efficacy and pharmacokinetics, and support the development of next-generation modulators for rare genetic variants. It also serves as a reference compound in laboratory assays studying ion channel activity and mutation-specific protein function.
Benefits
Ivacaftor offers several benefits in clinical and research settings due to its targeted mechanism of action and pharmacological properties. By directly potentiating CFTR protein activity, it improves chloride ion transport, reduces mucus accumulation, and alleviates symptoms associated with cystic fibrosis. The compound demonstrates good oral bioavailability, enabling effective systemic delivery, and has been shown to improve lung function and quality of life in patients with responsive mutations. In research, its defined chemical structure and selective activity allow reproducible studies on CFTR modulation, facilitating the development of combination therapies and personalized treatment strategies. These properties make Ivacaftor a valuable tool in both therapeutic and experimental contexts.
Conclusion
Ivacaftor is a targeted pharmaceutical agent widely used for cystic fibrosis treatment and CFTR-related research. Its applications in improving chloride channel function, combined with benefits such as efficacy, bioavailability, and mutation-specific activity, make it a critical compound for patient therapy and laboratory studies. The compound continues to support advances in precision medicine and the development of effective treatments for genetic disorders affecting CFTR protein function.
Previous
Bis(4-nitrophenyl) Carbonate丨CAS 5070-13-3
Next